Not finding it? Sign in to also search OpenAlex live.
-
Abstract 5163: A colon cancer survivor-derived antibody recognizes a previously unidentified truncated, O-mannosylated 70kDa variant of E-cadherin2020 Cancer Research conference-abstract Medicine Monoclonal and Polyclonal Antibodies Research cited by 1 patent
Martijn Kedde, Tim Beaumont, Sabrina J. Merat, Mark J. Kwakkenbos, Lina Bartels, Dorien van de Berg, +14 more
0citations -
499 AT1636, a colon cancer survivor-derived antibody recognizes a previously unidentified truncated, O-mannosylated 70kDa variant of E-cadherin2020 Regular and Young Investigator Award Abstracts conference-abstract Medicine Monoclonal and Polyclonal Antibodies Research Open access
Tim Beaumont, Martijn Kedde, Sabrina J. Merat, Mark J. Kwakkenbos, Lina Bartels, Dorien van de Berg, +16 more
0citations -
Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial
Tsewang Tashi, Olivier Hermine, Mariana Castells, Mar Guilarte, Vito Sabato, Marcus Maurer, +26 more
19citations -
Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies
Andrew Charles Perkins, Vincent Ribrag, William E. Shomali, Rosa María Ayala, Claire N. Harrison, Stephen T. Oh, +2 more
14citations -
Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Vikas Gupta, John O Mascarenhas, Haris Ali, David M. Ross, Abdulraheem Yacoub, Tania Jain, +27 more
10citations -
MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
2citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
1citations -
Late Breaking Abstract - Impact of COVID-19 on patients with severe alpha1 antitrypsin deficiency: the IMCA1 study of the EARCO ERS Clinical Research Collaboration, preliminary findings
David G. Parr, Christian Friedrich Clarenbach, Joanna Chorostowska‐Wynimko, Angelo Guido Corsico, Ilaria Ferrarotti, Lourdes Lázaro-Asegurado, +8 more
0citations -
Abstract 1802: Personalization of oncolytic virus therapy: Heterogenous anti-tumor responses in preclinical prostate and bladder cancer models2023 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Virus-based gene therapy research
Thijs J. Janssen, Geertje van der Horst, Arjanneke F. van de Merbel, Maaike H. van der Mark, Martine L.M. Lamfers, Bernadette G. van den Hoogen, +8 more
0citations -
Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study.2025 Journal of Clinical Oncology conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments Open access cited by 1 patent
Xiaohui Niu, Vinod Ravi, Javier Martín‐Broto, Yong Jian Zhou, Albiruni Ryan Abdul Razak, Ramy Saleh, +13 more
6citations